10 Best Rising Penny Stocks to Buy According to Analysts

3. TuHURA Biosciences, Inc. (NASDAQ:HURA)

Price: $4.11

1-Month Performance: 69.63%

Analyst Upside Potential: 167.97%

Number of Hedge Fund Holders: 3

TuHURA Biosciences, Inc. (NASDAQ:HURA) is a registration-stage biotechnology company that specializes in immuno-oncology. Its lead product IFx-2.0 is a personalized cancer vaccine. The company is to initiate a pivotal, randomized, placebo-controlled Phase III trial of IFx-2.0 as an adjunctive therapy to Keytruda.

On March 3rd, H.C. Wainwright initiated coverage on the stock with a Buy rating and a $13 price target. The firm noted that IFx-2.0 has demonstrated an encouraging overall response rate in phase 1b. The year 2024 was a pivotal year for TuHURA Biosciences, Inc. (NASDAQ:HURA) as it became listed on the NASDAQ exchange. The company also raised capital to meet the FDA’s manufacturing requirement to initiate phase 3. Management noted that they are advancing into the last stage of the clinical program in 2025 and anticipate completing the enrollment for phase 3 by next year. It is one of the best penny stocks to buy according to analysts.